Latest filing published 28 Dec 2018 for CRISPR Therapeutics AG, €278k.
Filing timeline
BuySaleInsider track record
Closed purchases
Based on 6 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- +116.5%Entry US$28.57 · Close at T+365 US$61.84
- +149.9%Entry US$26.41 · Close at T+365 US$66.01
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Vertex Pharmaceuticals (Europe) Ltd: trading record in brief
All filings by Vertex Pharmaceuticals (Europe) Ltd on record concern CRISPR Therapeutics AG. Over a trading history stretching from 21 December 2018 to 27 December 2018, the count stands at 6 filings.
Every open-market trade on record is a purchase: 6 purchases worth €2.8M, and no sale. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant.
The median purchase comes to €363k. None of the 6 purchases we analysed coincided with buying by another insider of the same company within 30 days. Ninety days after publication, 6 purchases show a median change of +29.5%, with the price up in 100% of them. Past outcomes like these are no guarantee of what comes next.
The newest entry dates from 28 December 2018: an open-market purchase of €278k, in CRISPR Therapeutics AG. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to Vertex Pharmaceuticals (Europe) Ltd
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 12,737 shares@ US$24.89429.9% of flowCommon SharesSEC:0001209191-18-064322:0Canonical exit: 26 Mar 2019 (T+90)
- 27,461 shares@ US$24.948721.5% of flowCommon SharesSEC:0001209191-18-064322:1Canonical exit: 27 Mar 2019 (T+90)
- 22,742 shares@ US$22.578416.0% of flowCommon SharesSEC:0001209191-18-064099:0Canonical exit: 21 Mar 2019 (T+90)
- 2,603 shares@ US$22.91471.9% of flowCommon SharesSEC:0001209191-18-064099:1Canonical exit: 24 Mar 2019 (T+90)
- 11,742 shares@ US$23.17668.6% of flowCommon SharesSEC:0001209191-18-064099:2Canonical exit: 24 Mar 2019 (T+90)
- 53,655 shares@ US$24.968742.1% of flowCommon SharesSEC:0001209191-18-064099:3Canonical exit: 24 Mar 2019 (T+90)
6 of 6 declarations
